Short-term efficacy of first-and second-line anlotinib therapy in patients with advanced non-small cell lung cancer

WANG Min; CHANG Ning; ZHANG Yong; ZHANG Jian

doi:10.13276/j.issn.2097-1656.2024.01.016

Abstract：Objective To evaluate the short-term efficacy and safety of anlotinib as first-and second-line therapy in patients with advanced non-small cell lung cancer(NSCLC)who cannot receive chemotherapy or targeted treatment,and to analyze the potential correlation between the number of treatment lines and prognosis.Methods The clinical data of stageⅢ/Ⅳ NSCLC patients who were treated with chemotherapy or targeted therapy and anlotinib as monotherapy were collected for retrospective analysis.A total of 69 stage Ⅲ/Ⅳ NSCLC patients who met the inclusion requirements were included,among which 26 patients who had never received antitumor therapy received first-line treatment of anlotinib(first-line treatment group),and 43 patients who were intolerant of/refractory to chemotherapy or targeted therapy received second-line treatment of anlotinib(second-line treatment group).Progression-free survival(PFS)of patients was the primary evaluation index,and the secondary observation indexes included objective response rate(ORR),disease control rate(DCR),and safety of anlotinib.Results The median PFS of 69 patients was 4.6 months(95％CI:4.21-5.00),and ORR and DCR were 15.9％and 84.1％,respectively.Among them,the ORR and DCR of 26 patients receiving first-line treatment of anlotinib were 26.9％and 84.6％,respectively.The ORR and DCR of 43 patients receiving second-line treatment of anlotinib were 9.3％and 83.7％,respectively.In this study,the common toxic and side effects of anlotinib were controllable,such as hypertension,hand-foot syndrome and oral mucositis.Conclusion Anlotinib has shown preliminary efficacy and tolerable safety in stage Ⅲ/Ⅳ NSCLC patients who have not received chemotherapy or targeted therapy,and the number of treatment lines of anlotinib can serve as an independent influencing factor for PFS.